| Bioactivity | Ulenistamab (PBP1510) is a first-in-class hunamised IgG1 monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF). Ulenistamab can be used for pancreatic cancer (PC) research[1]. |
| Invitro | Ulenistamab (PBP1510) 抑制 PC 细胞系（CFPAC-1 和 BxPC-3）的增殖。同时，PC 细胞系的迁移和侵袭显着减少[1]。 |
| In Vivo | 在 6 只猴子的单剂量研究中检查了 Ulenistamab (PBP1510)（高达 20 mg/kg）的药代动力学 (PK) 特征和免疫原性。在猴子研究中，在低剂量和高剂量下观察到全身暴露量按剂量比例增加[1]。 |
| Name | Ulenistamab |
| CAS | 2415259-90-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kedar Diwakar Mandakhalikar, et al. First-in-class monoclonal antibody (mAb) PBP1510 targeting pancreatic adenocarcinoma upregulated factor (PAUF) for pancreatic cancer (PC) treatment: Preclinical perspectives. Journal of Clinical Oncology 2022 40:16_suppl, e16274-e16274. |